Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;67(15):2153-71.
doi: 10.2165/00003495-200767150-00004.

Treatment of acute lymphoblastic leukaemia : a new era

Effrosyni Apostolidou  1 , Ronan Swords, Yesid Alvarado, Francis J Giles
Affiliations
Review

Treatment of acute lymphoblastic leukaemia : a new era

Effrosyni Apostolidou et al. Drugs. 2007.

Abstract

Acute lymphocytic leukaemia (ALL) is a heterogeneous group of disorders that result from the clonal proliferation and expansion of malignant lymphoid cells in the bone marrow, blood and other organs. Distinct clinicopathological ALL entities have been identified, resulting in the adoption of risk-oriented treatment approaches. Advances in ALL therapy have led to long-term survival rates of >80% in children. However, only approximate, approximately 30-40% of adults achieve long-term disease-free survival. Contemporary ALL treatment programmes include induction, intensified consolidation, maintenance phases and CNS prophylaxis. The optimal treatment of Philadelphia chromosome-positive patients requires the addition of BCR-ABL tyrosine kinase inhibitors, such as imatinib, whereas allogeneic stem-cell transplantation remains the preferred approach for high-risk patients in first remission. Since only approximate, approximately 38% of adult ALL patients are free of disease 5 years after diagnosis and the outcome of salvage chemotherapy is very poor (complete remission rates of 20-30%, median survival of 3-6 months), novel agents are desperately required. Of those currently in clinical studies, the outlook for sphingosomal vincristine, pegylated asparaginase (pegaspargase), liposomal annamycin, ABT-751, pemetrexed, talotrexin, nelarabine and the novel BCR-ABL kinase inhibitors is discussed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Expert Opin Investig Drugs. 2003 May;12(5):853-63 - PubMed
    1. Cancer Res. 1977 Feb;37(2):535-40 - PubMed
    1. Lancet Oncol. 2005 Aug;6(8):548 - PubMed
    1. Blood. 2007 Feb 1;109(3):944-50 - PubMed
    1. Br J Cancer. 2006 Jun 19;94(12):1765-9 - PubMed

Publication types

MeSH terms

LinkOut - more resources